|Mr. Timo Lappalainen||CEO, Pres & Chairman of the Exec. Management Board||1.54M||N/A||1962|
|Mr. Jari Karlson M.Sc., M.Sc. (Econ.)||CFO, Sr. VP of Animal Health & Member of the Exec. Management Board||N/A||N/A||1961|
|Mr. Olli Huotari||Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board||N/A||N/A||1966|
|Ms. Satu AhomÃ¤ki||Sr. VP of Commercial Ops, Global Sales & Proprietary Products and Member of the Exe. Mgmt. Board||N/A||N/A||1966|
|Dr. Liisa Hurme||Sr. VP of Supply Chain & Member of the Exec. Management Board||N/A||N/A||1967|
|Ms. Virve Laitinen||Sr. VP of Specialty Products & Member of Exec. Management Board||N/A||N/A||1972|
|Prof. Outi Vaarala M.D., Ph.D.||Sr. VP for R&D and Member of Exec. Management Board||N/A||N/A||1962|
|Mr. Tuukka Hirvonen M.Sc.(Soc.)||Investor Relations & Financial Communications Officer||N/A||N/A||N/A|
|Ms. Terhi Ormio||VP of Communications||N/A||N/A||N/A|
|Prof. Heikki Joensuu M.D., Ph.D.||R&D Global Head of Therapy Area Oncology||N/A||N/A||N/A|
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj is headquartered in Espoo, Finland.
Orion Oyj’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 3; Board: 2; Shareholder rights: 10; Compensation: 9.